Vivani Medical Statistics
Total Valuation
Vivani Medical has a market cap or net worth of $114.27 million. The enterprise value is $116.90 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vivani Medical has 84.65 million shares outstanding. The number of shares has increased by 13.47% in one year.
| Current Share Class | 84.65M |
| Shares Outstanding | 84.65M |
| Shares Change (YoY) | +13.47% |
| Shares Change (QoQ) | +19.51% |
| Owned by Insiders (%) | 48.57% |
| Owned by Institutions (%) | 7.64% |
| Float | 37.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.56 |
| P/TBV Ratio | 7.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.71, with a Debt / Equity ratio of 1.20.
| Current Ratio | 2.71 |
| Quick Ratio | 2.56 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -159.62% and return on invested capital (ROIC) is -48.17%.
| Return on Equity (ROE) | -159.62% |
| Return on Assets (ROA) | -42.55% |
| Return on Invested Capital (ROIC) | -48.17% |
| Return on Capital Employed (ROCE) | -84.04% |
| Weighted Average Cost of Capital (WACC) | 19.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$633,548 |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.07% in the last 52 weeks. The beta is 3.37, so Vivani Medical's price volatility has been higher than the market average.
| Beta (5Y) | 3.37 |
| 52-Week Price Change | +31.07% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 1.34 |
| Relative Strength Index (RSI) | 60.35 |
| Average Volume (20 Days) | 322,197 |
Short Selling Information
The latest short interest is 532,131, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 532,131 |
| Short Previous Month | 322,575 |
| Short % of Shares Out | 0.63% |
| Short % of Float | 1.43% |
| Short Ratio (days to cover) | 2.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.56M |
| Pretax Income | -26.61M |
| Net Income | -26.61M |
| EBITDA | -27.13M |
| EBIT | -27.56M |
| Earnings Per Share (EPS) | -$0.43 |
Full Income StatementBalance Sheet
The company has $16.23 million in cash and $18.86 million in debt, with a net cash position of -$2.62 million or -$0.03 per share.
| Cash & Cash Equivalents | 16.23M |
| Total Debt | 18.86M |
| Net Cash | -2.62M |
| Net Cash Per Share | -$0.03 |
| Equity (Book Value) | 15.73M |
| Book Value Per Share | 0.21 |
| Working Capital | 11.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.32 million and capital expenditures -$1.17 million, giving a free cash flow of -$25.49 million.
| Operating Cash Flow | -24.32M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 424,000 |
| Net Borrowing | 11,000 |
| Free Cash Flow | -25.49M |
| FCF Per Share | -$0.30 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vivani Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.47% |
| Shareholder Yield | -13.47% |
| Earnings Yield | -23.29% |
| FCF Yield | -22.31% |
Analyst Forecast
The average price target for Vivani Medical is $3.50, which is 159.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 159.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
